Related Experiment Video
Updated: Feb 3, 2026

Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
Development and validation of analytical methodologies for the quantification of PCK3145 and PEG-PCK3145 in mice
Charikleia Danika1, Mohamed A El Mubarak1, Iliana Leontari1
1Laboratory of Pharmacokinetics, Department of Pharmacy, University of Patras, Patras, Greece.
Abstract:
PCK3145 is an anti-metastatic synthetic peptide against prostate cancer. The objective of the study is to develop and validate novel and sensitive methods for the determination of PCK3145 and Pegylated PCK3145 in mouse plasma. An LC-MS/MS method was developed and validated for the determination of PCK3145 giving high sensitivity and linearity in the range of 0.125-4.0 μg/mL. PCK3145 characterised by short half-life, therefore, it was conjugated with the poly ethylene glycol (PEG). However, LC-MS/MS has been more difficult to apply for the quantitative analysis of PEGylated peptides due to the large size. A UHPLC-UV method was developed and validated for the determination of PEG-PCK3145, with linearity of 0.05-2.0 mg/mL. In order to further improve the sensitivity for the detection of PEG-PCK3145, an indirect ELISA method was used. It was found that this method was capable of detecting PCK3145 through the quantification of PEG with excellent sensitivity found at 0.132 ng/mL. The in vitro proteolytic stability of PCK3145 and PEG-PCK3145 in mouse plasma and whole blood was studied by LC-MS/MS and UHPLC, respectively. The LC-MS/MS and ELISA methods can be applied for monitoring levels of PCK3145 in mouse plasma for in vivo pharmacokinetic and bioavailability animal studies.
Related Concept Videos
Development of Analytical Methods
Reliability and Validity
In Vitro Drug Release Testing: Overview, Development and Validation
Analyte Adsorption and Distribution
Jung's Analytical Theory
Data Validation
Key parameters for method validation include:

